Compare AIOT & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIOT | CRBP |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 665.1M | 170.3M |
| IPO Year | N/A | N/A |
| Metric | AIOT | CRBP |
|---|---|---|
| Price | $5.56 | $8.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $10.50 | ★ $50.29 |
| AVG Volume (30 Days) | ★ 1.3M | 502.6K |
| Earning Date | 02-09-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $425,867,000.00 | N/A |
| Revenue This Year | $23.71 | N/A |
| Revenue Next Year | $9.22 | $100.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 92.93 | N/A |
| 52 Week Low | $3.70 | $4.64 |
| 52 Week High | $8.71 | $20.56 |
| Indicator | AIOT | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 64.10 | 29.88 |
| Support Level | $5.34 | $7.97 |
| Resistance Level | $5.44 | $8.51 |
| Average True Range (ATR) | 0.22 | 0.63 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 98.25 | 9.26 |
PowerFleet Inc is engaged in Internet-of-Things (IoT) solutions providing valuable business intelligence for managing high-value enterprise assets that improve operational efficiencies. It provide critical information that powers unified operations throughout organizations. It is solving the challenge of inefficient data collection, real-time visibility, and analysis that leads to transformative business operations. Its SaaS cloud-based applications take data from IoT devices and ecosystem of third-party and partner applications to present actionable information for customer.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.